Show simple item record

dc.creatorKovačević, Milena
dc.creatorVezmar-Kovačević, Sandra
dc.creatorMiljković, Branislava
dc.creatorRadovanović, Slavica
dc.creatorStevanović, Predrag
dc.date.accessioned2019-09-02T11:59:16Z
dc.date.available2019-09-02T11:59:16Z
dc.date.issued2017
dc.identifier.issn1368-5031
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/2874
dc.description.abstractAim: The aim was to describe the type and prevalence of potentially relevant drug-drug interactions (pDDIs) in a population of patients admitted for cardiovascular diseases (CVD), and management strategies for reducing the occurrence of pDDIs. Methods: A retrospective cross-sectional study was performed on Cardiology ward of University Clinical Hospital Center in Belgrade, Serbia. A total of 527 patients, with more than one prescription during hospital stay, were enrolled in this study. Data were obtained from medical records. LexiInteract was used as the screening tool. Results: At least one potentially relevant pDDI was identified in 83.9% of patients. Occurrence was significantly more prevalent in patients with higher number of drugs, multimorbidity, longer length of stay, arrhythmia, heart failure, infectious and respiratory disease. About 13% of pDDIs exposures were accompanied with concurrent renal or liver disease, as an additional risk for DDI manifestation. Among CVD, patients with a history of myocardial infarction possessed the highest additional risk. The most common potential clinical outcome was the effect on cardiovascular system 48.5%, renal function and/or potassium 22.3%, bleeding 9.5%, impaired glucose control 6.8% and digoxin toxicity 4.6%. Main management strategies to avoid X or D class included using paracetamol instead of NSAID or alternative NSAID (38%), alternative antibiotic or antifungal (20.4%), H-2 receptor antagonist instead of PPI (8.3%), avoiding therapeutic duplication (7.3%), and alternative HMG-CoA reductase inhibitor (7%). Heart rate, blood pressure, electrolytes/potassium and blood glucose could have been employed in monitoring for potential consequence of 72.2% C class pDDIs. Conclusions: Use of drug interaction screening tools can be beneficial risk mitigation strategy for potentially relevant pDDIs in CVD patients. DDI screening software could be linked to the patient's laboratory results or clinical data regarding renal or liver function, as an approach to reinforce DDIs alert quality.en
dc.publisherWiley, Hoboken
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175023/RS//
dc.rightsopenAccess
dc.sourceInternational Journal of Clinical Practice
dc.titleThe prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional studyen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractМиљковић, Бранислава; Везмар-Ковачевић, Сандра; Стевановић, Предраг; Радовановић, Славица; Ковачевић, Милена;
dc.citation.volume71
dc.citation.issue10
dc.citation.other71(10): -
dc.citation.rankM22
dc.identifier.wos000412547500007
dc.identifier.doi10.1111/ijcp.13005
dc.identifier.pmid28869702
dc.identifier.scopus2-s2.0-85028894332
dc.identifier.fulltexthttps://farfar.pharmacy.bg.ac.rs//bitstream/id/1499/2872.pdf
dc.identifier.rcubconv_3961
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record